How many GLP-1 sellers publish a price

What was read, and how

588 sellers, 1886 pages opened between them, of which 1737 loaded and 149 did not. Those pages carried 3317 dollar figures, 299 of them the same figure printed twice, leaving 3018 distinct prices. All of it was read on a single day, September 2026.

A price counts as published only if you can see it. A number hidden in a page’s code that never appears on screen counts as absent; a price behind a tab or an accordion you can open counts as published, because you can reach it. What each price was for was then settled by reading the words around it, not by pattern-matching.

Three companies from the original list are left out of every number here: one isn’t a seller, and two are domains that no longer belong to the companies they name. A domain that changed hands cannot be reported as that company’s page.

These pages were read once, on one day. Nothing here is a trend or a price movement: there is no earlier reading to compare against.

Where the numbers came from

Each of the 588 sellers falls into exactly one of six outcomes. The six sum to 588; nothing was dropped for being inconvenient, including the sellers whose sites would not render for this reading at all.

180 of the 588 published nothing this reading could tie to a GLP-1 — either no visible figure at all, or figures with nothing near them naming one of these drugs. That is a statement about what could be shown, not a claim those companies sell nothing: a price with no drug named beside it cannot be proved to be that drug’s price, and this site would rather report the gap than guess across it.

From every seller read to the ones with a comparable price

The same 588 sellers, narrowed one rule at a time. Each step below is a subset of the one above it.

61 of 588 is 10 per cent. That is the honest size of the comparable GLP-1 market as its own websites describe it — not the size of the market, which is far larger, but the share of it that published a number a buyer can weigh against another number.

The three narrowings, and the rule each applies

Three rules do almost all of the narrowing, and each one is a decision about what can be shown rather than a judgment of a company.

A figure has to be tied to a drug. 408 sellers cleared this and 180 did not. The test is whether the drug is named on the page the figure was read on, or in the text immediately around it. A price on a page that never says what it is for is a price about which nothing can be said.

A rate has to recur. 210 of the 408 publish figures tied to a GLP-1 without any of them being a standing monthly rate. A prepay total for three months and a monthly rate are different quantities, and putting them in one column would be the comparison this site exists to refuse.

The rate has to name a molecule, on that molecule’s own page. 81 sellers publish a standing monthly rate this site still cannot compare, because the figure names a GLP-1 without saying which, or names a brand-name product, or was read on a general page rather than a page scoped to the drug. What drug a GLP-1 price is for counts that in full, across every published figure rather than one per seller.

The reasons overlap: one figure can fail two of these tests at once. That is why each rule is stated with its own two counts rather than drawn as a chart, which would add up to more than the 588 sellers it describes while looking like a neat split.

What this count is not

This is not a market size. It counts companies whose sites could be found and opened, and a seller that advertises nowhere a reader can reach was never in the count. It is not a ranking either: no company is named on this page, and no letter grade, score or order of medical quality is published on this site.

It is also not a price comparison. The analysis above counts published prices without comparing their amounts — 2608 of the 3018 figures read are not a comparable monthly rate, and a great many were read on pages that never say which drug they price. Where prices are printed on this site they come from the 61 sellers whose figure states what it buys, each one shown with the seller’s own words for what the money covers.

The roster page for every one of the 117 sellers with a comparable rate is under every seller we have read, including the 56 that carry no price and say why. What is counted, and what each measurement is worth, is on how we grade.

The other findings

Each one says how many sellers it counted, and the counts differ on purpose: a question can only be asked of the sellers who published enough to answer it.

• What drug the price is for

  Whether a published GLP-1 figure says which drug it prices, and how often the number sits on a page that never names one.

  Counted over 3018 published figures across 408 sellers.

• Compounded or branded

  How often a seller says, beside the figure, whether the drug is compounded or the FDA-approved product — and the one case where it almost always does.

  Counted over 3018 published figures across 408 sellers.

• What sellers do not publish

  The pharmacy, the product class, the dose schedule and the cancellation terms: four things a reader needs before buying, and how many sellers publish each one.

  Counted over 61 sellers whose figure states what it buys.

• The tirzepatide premium

  What the same seller charges for tirzepatide against semaglutide — and why most sellers who sell both do not publish a pair a reader can put side by side.

  Counted over 46 sellers publishing a figure for both molecules.

• What a price buys, by dose

  Whether a GLP-1 price changes with the dose, and how many sellers publish a figure that states which dose it buys at all.

  Counted over 61 of 117 sellers on this roster.

Where the comparable sellers are compared

One board per buying decision, built from the 117 sellers above whose rate is comparable.

• Semaglutide providers55 listed

  Compare semaglutide plans, pharmacy details and cancellation terms.

• Tirzepatide providers52 listed

  Compare tirzepatide plans, pharmacy details and cancellation terms.

• Providers that publish a price before the intake60 listed

  See providers that show medication prices before the intake.

• GLP-1 providers with a published price, compared60 listed

  Compare advertised prices, plan commitments and what’s included.

• GLP-1 providers for readers paying cash53 listed

  Compare plans whose published price includes medication.

• GLP-1 telehealth providers61 listed

  Compare GLP-1 prescribers, pharmacy details, care and cancellation terms.

Every board above was read September 2026 and carries its own dated, counted title.